Compare Campbell Soup Co. (CPB) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Smith & Nephew plc — how do they compare? Campbell Soup Co. trades at $19.31 (market cap $5.78B), while Smith & Nephew plc trades at $27.22 (market cap $11.10B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Campbell Soup Co. pays the higher dividend (5.16%). Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Smith & Nephew plc for 120 Days on average.
| CPB | SNN | |
|---|---|---|
Market Cap | $5.78B | $11.10B |
Volume | 11,705,427 | 1,051,703 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $37.17 |
52-Week Low | $18.90 | $26.42 |
Typical Hold Time | 98 Days | 120 Days |
Enterprise Value | $12.83B | $14.13B |
Dividend Yield | 5.16% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $18.90, down 0.53% with bearish technical indicators. The company faces margin compression with net income margin at 4.14% and recently cut its dividend by 36% to strengthen the balance sheet. Revenue grew to $10.25B in 2025 but profitability remains under pressure. Analyst consensus shows cautious sentiment with 55% hold ratings and a $19.67 price target.
The outlook remains challenging with weak FY2027 guidance and ongoing restructuring. The $500 million cost savings program and Rao's brand growth offer potential upside, but investors face risks from declining sales, margin pressure, and competitive headwinds in the packaged foods sector.
Smith & Nephew (SNN) trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio, though the stock faces headwinds from analyst downgrades and CFO departure news.
The outlook is cautious; while fundamentals show profitability growth, the stock's proximity to lows and mixed analyst sentiment (26% buy, 65% hold) suggest limited near-term upside. Key risks include competitive pressures and execution challenges, but the stable dividend and institutional interest offer some support for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
